Frontiers in Endocrinology (Dec 2022)

Metabolic syndrome and metastatic prostate cancer correlation study, a real-world study in a prostate cancer clinical research center, Xinjiang, China

  • Hengqing An,
  • Hengqing An,
  • Hengqing An,
  • Dongsheng Ma,
  • Dongsheng Ma,
  • Yujie Mei,
  • Lulu Wang,
  • Abudukeyoumu Maimaitiyiming,
  • Tao Zhuo,
  • Tao Zhuo,
  • Renaguli Aihaiti,
  • Renaguli Aihaiti,
  • Ke Bu,
  • Xin Huang,
  • Xin Huang,
  • Kaige Zhang,
  • Kaige Zhang,
  • Miao Yao,
  • Miao Yao,
  • Chenyang Ling,
  • Weizun Li,
  • Ning Tao

DOI
https://doi.org/10.3389/fendo.2022.1090763
Journal volume & issue
Vol. 13

Abstract

Read online

ObjectiveThe aim of this study was to investigate the relevance of metabolic syndrome (MetS) and metabolic scores to the occurrence, progression and prognosis of metastatic prostate cancer (mPCA), assessing the definition of the variables of metabolic syndrome, and the potential mechanisms of MetS and mPCA.MethodsData were obtained from the database of prostate cancer follow-up at the Urology Centre of the First Affiliated Hospital of Xinjiang Medical University (N=1303). After screening by inclusion and exclusion criteria, clinical data of 190 patients diagnosed with mPCA by pathology and imaging from January 2010 to August 2021 were finally included, including 111 cases in the MetS group and 79 cases in the Non-MetS group.ResultsThe MetS group was higher than the Non-MetS group: T stage, Gleasson score, initial PSA, tumor load, PSA after 7 months of ADT (P<0.05),with a shorter time to progression to CRPC stage(P<0.05)[where the time to progression to CRPC was relatively shorter in the high metabolic score subgroup of the MetS group than in the low subgroup (P<0.05)].Median survival time was significantly shorter in the MetS group than in the Non-MetS group (P<0.05),and there was a correlation with metabolic score, with the higher metabolic score subgroup having a lower survival time than the lower metabolic score subgroup (P<0.05).ConclusionThose with mPCA combined with MetS had lower PSA remission rates, more aggressive tumors, shorter time to progression to CRPC and shorter median survival times than those with mPCA without MetS.Tumour progression and metabolic score showed a positive correlation, predicting that MetS may promote the progression of mPCA, suggesting that MetS may be a risk factor affecting the prognosis of mPCA.

Keywords